PCRX Pacira BioSciences, Inc. Stock Quote

PCRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	17.98	EPS (ttm)	3.32	Insider Own	0.50%	Shs Outstand	43.83M	Perf Week	-1.45%
Market Cap	2.57B	Forward P/E	15.02	EPS next Y	3.97	Insider Trans	-66.57%	Shs Float	43.66M	Perf Month	-6.97%
Income	147.70M	PEG	0.53	EPS next Q	0.68	Inst Own	-	Short Float	16.24%	Perf Quarter	-14.87%
Sales	443.00M	P/S	5.80	EPS this Y	32.10%	Inst Trans	-1.80%	Short Ratio	15.61	Perf Half Y	0.37%
Book/sh	14.85	P/B	4.02	EPS next Y	35.71%	ROA	12.70%	Target Price	80.08	Perf Year	33.93%
Cash/sh	13.71	P/C	4.35	EPS next 5Y	33.85%	ROE	26.30%	52W Range	42.67 - 80.00	Perf YTD	-0.33%
Dividend	-	P/FCF	66.34	EPS past 5Y	136.60%	ROI	15.10%	52W High	-25.45%	Beta	1.07
Dividend %	-	Quick Ratio	2.80	Sales past 5Y	11.50%	Gross Margin	73.10%	52W Low	39.77%	ATR	2.08
Employees	624	Current Ratio	3.10	Sales Q/Q	12.60%	Oper. Margin	9.20%	RSI (14)	41.04	Volatility	3.05% 3.32%
Optionable	Yes	Debt/Eq	0.72	EPS Q/Q	18.30%	Profit Margin	33.30%	Rel Volume	2.88	Prev Close	60.45
Shortable	Yes	LT Debt/Eq	0.49	Earnings	May 04 BMO	Payout	0.00%	Avg Volume	453.99K	Price	59.64
Recom	2.10	SMA20	-3.98%	SMA50	-5.70%	SMA200	-6.81%	Volume	1,309,518	Change	-1.34%

Apr-21-21

Resumed

JP Morgan

Neutral

$70

Apr-09-21

Initiated

Berenberg

Buy

$93

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$86

Feb-11-21

Downgrade

Northland Capital

Outperform → Market Perform

$72 → $75

Jan-21-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

$75

Sep-21-20

Upgrade

Northland Capital

Market Perform → Outperform

$58 → $67

Jul-06-20

Reiterated

Needham

Buy

$52 → $64

May-27-20

Initiated

Guggenheim

Neutral

Apr-07-20

Initiated

Northland Capital

Outperform

$50

Mar-20-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$44

Feb-24-20

Reiterated

H.C. Wainwright

Buy

$60 → $63

Jan-24-20

Initiated

SunTrust

Buy

Jan-23-20

Initiated

SunTrust

Buy

Nov-06-19

Initiated

BTIG Research

Buy

$56

Jun-11-19

Initiated

Barclays

Overweight

$52

May-06-19

Upgrade

Mizuho

Underperform → Neutral

$29 → $38

May-02-19

Upgrade

Stifel

Sell → Hold

$45

Feb-01-19

Downgrade

Mizuho

Neutral → Underperform

Aug-06-18

Downgrade

BofA/Merrill

Buy → Neutral

Apr-09-18

Reiterated

H.C. Wainwright

Buy

$45 → $48

Jun-08-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021 GlobeNewswire
Jun-03-21 11:31AM	How Has PCRX Performed 30 Days Post Earnings Zacks
May-26-21 09:23AM	Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries Benzinga
08:00AM	Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block GlobeNewswire
May-25-21 08:00AM	Pacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference GlobeNewswire
May-18-21 08:00AM	Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL GlobeNewswire
May-12-21 08:00AM	Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-11-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021 GlobeNewswire
May-05-21 08:11AM	Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat Zacks
May-04-21 02:30PM	Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Q1 Earnings Lag Estimates Zacks
08:00AM	Pacira BioSciences Reports First Quarter 2021 Financial Results and Business Update GlobeNewswire
06:45AM	Pacira Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Apr-21-21 07:30AM	Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021 GlobeNewswire
Apr-20-21 07:30AM	Spine BioPharma Announces Investment by Pacira Biosciences PR Newswire
07:30AM	Pacira BioSciences Announces Investment in Spine BioPharma GlobeNewswire
Apr-14-21 04:00PM	Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology GlobeNewswire
Apr-07-21 08:00AM	Pacira Reports Preliminary Net Product Sales of $118.7 Million for the First Quarter of 2021 GlobeNewswire
Mar-30-21 05:46AM	Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly Simply Wall St.
Mar-27-21 11:31AM	Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-23-21 09:36AM	Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients Zacks
Mar-22-21 06:42PM	Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® (bupivacaine liposome injectable suspension) in Pediatric Patients GlobeNewswire
Mar-17-21 01:10PM	Halozyme Stock Joins The 80-Plus RS Rating Club Investor's Business Daily
Mar-15-21 01:05PM	Stocks Showing Leadership: Covid Recovery Play Ligand Earns Key Rating Jump Investor's Business Daily
Mar-09-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021 GlobeNewswire
Mar-03-21 07:30AM	Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference GlobeNewswire
Feb-26-21 08:58AM	Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss Zacks
Feb-25-21 04:01PM	Pacira BioSciences, Inc. (PCRX) Q4 2020 Earnings Call Transcript Motley Fool -5.54%
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results GlobeNewswire
06:30AM	Pacira Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 02:49PM	Pacira Pharmaceuticals Getting Closer To Key Technical Measure Investor's Business Daily
Feb-18-21 07:30AM	Pacira to Report 2020 Financial Results on Thursday February 25, 2021 GlobeNewswire
Feb-14-21 01:32PM	15 Best Small-Cap Healthcare Stocks to Buy Insider Monkey
Feb-10-21 07:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021 GlobeNewswire
Jan-29-21 03:32AM	Here's Why I Think Pacira BioSciences (NASDAQ:PCRX) Is An Interesting Stock Simply Wall St.
Jan-26-21 03:39PM	Composite Rating For Pacira Pharmaceuticals Rises To 97 Investor's Business Daily
08:00AM	Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics GlobeNewswire
Jan-15-21 11:40AM	AMRX or PCRX: Which Is the Better Value Stock Right Now? Zacks
Jan-12-21 12:48PM	Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Jan-08-21 04:18PM	Stocks Rebound Into The Close; Tesla Contributes To Nasdaq 100's 1.3% Jump Investor's Business Daily
Jan-07-21 04:10PM	Nasdaq Soars As Indexes Hit Record Highs; Medical, Energy, Auto Stocks Among Breakouts Investor's Business Daily +7.50%
07:30AM	Pacira Reports Record Revenue for 2020 of $429.6 Million GlobeNewswire
Jan-06-21 07:30AM	Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-20 02:39AM	Pacira BioSciences (NASDAQ:PCRX) Shareholders Booked A 38% Gain In The Last Three Years Simply Wall St.
Dec-09-20 04:40PM	Dow Jones Falls, Nasdaq Leads Market Lower On Stimulus Talks Investor's Business Daily -7.41%
07:30AM	Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020 GlobeNewswire
Nov-24-20 07:30AM	Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-19-20 10:08AM	Pacira (PCRX) Gets European Commission Approval for Exparel Zacks
Nov-18-20 07:30AM	Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain GlobeNewswire
Nov-16-20 01:48PM	Dow Jones Rises 330 Points To Record High On Positive Vaccine Data Investor's Business Daily
Nov-13-20 10:40AM	Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Nov-11-20 01:27PM	IBD 50 Stocks To Watch: This Pharma Stock On 115% Run Eyes Buy Point Investor's Business Daily
08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020 GlobeNewswire
Nov-10-20 07:30AM	Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-09-20 12:42PM	Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? Simply Wall St. +13.73%
Oct-30-20 12:57PM	Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y Zacks
03:01AM	Pacira BioSciences, Inc. (PCRX) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 09:15AM	Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates Zacks
08:00AM	Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update GlobeNewswire
06:30AM	Pacira Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-22-20 12:33PM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Oct-21-20 07:30AM	Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain GlobeNewswire
06:25AM	Pacira BioSciences (PCRX) Enters Oversold Territory Zacks
Oct-20-20 07:30AM	Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020 GlobeNewswire
Oct-19-20 11:30AM	Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year? Zacks
Oct-07-20 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020 GlobeNewswire
Sep-21-20 11:56AM	Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU Zacks
Sep-18-20 08:07AM	Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain GlobeNewswire
Sep-16-20 02:55PM	Here is What Hedge Funds Think About Pacira Biosciences Inc (PCRX) Insider Monkey
Sep-15-20 07:30AM	IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs GlobeNewswire
Sep-11-20 07:30AM	Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-09-20 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020 GlobeNewswire
Sep-05-20 11:31AM	Pacira (PCRX) Up 4.1% Since Last Earnings Report: Can It Continue? Zacks
Aug-06-20 08:00AM	Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update GlobeNewswire
Aug-05-20 04:05PM	Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
07:30AM	Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia GlobeNewswire
Aug-04-20 07:30AM	Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients GlobeNewswire
Jul-30-20 07:30AM	Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020 GlobeNewswire
Jul-28-20 05:03PM	Pacira BioSciences Announces Settlement of Government Investigation GlobeNewswire
Jul-12-20 12:43PM	Did Hedge Funds Make The Right Call On Pacira Biosciences Inc (PCRX)? Insider Monkey
Jul-07-20 07:51PM	Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025 GlobeNewswire
Jul-06-20 04:02PM	Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes GlobeNewswire
04:01PM	Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020 GlobeNewswire
Jul-02-20 07:30AM	Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes GlobeNewswire
Jun-29-20 09:00AM	U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller Reuters +17.99%
Jun-16-20 07:30AM	Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-10-20 04:36PM	Hedge Funds Souring On Pacira Biosciences Inc (PCRX) Insider Monkey
May-27-20 07:30AM	Pacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference GlobeNewswire
May-13-20 07:30AM	Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference GlobeNewswire
May-07-20 08:00AM	Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update GlobeNewswire
May-04-20 07:30AM	Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer GlobeNewswire +5.42%
Apr-30-20 07:30AM	Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 GlobeNewswire
Apr-23-20 08:59AM	Why Pacira BioSciences, Inc.'s (NASDAQ:PCRX) CEO Pay Matters To You Simply Wall St.
Apr-07-20 05:00PM	Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds? Insider Monkey
Apr-06-20 08:00AM	How This Top Fund Manager Seeks Stocks That Benefit From The Coronavirus Stock Market Investor's Business Daily
Mar-21-20 11:30AM	Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-17-20 09:53AM	Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock Zacks
Mar-13-20 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why Zacks +5.98%
11:40AM	PCRX or ZTS: Which Is the Better Value Stock Right Now? Zacks
Mar-10-20 10:24AM	Why Pacira (PCRX) Could Be an Impressive Growth Stock Zacks

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riker Lauren Bullaro	Vice President, Finance	Jun 11	Sale	59.85	2,003	119,880	12,731	Jun 11 08:39 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 10	Sale	59.60	5,689	339,063	22,268	Jun 11 08:38 PM
Manning Donald C.	Chief Medical Officer	Jun 08	Sale	61.14	2,600	158,964	23,520	Jun 10 06:07 PM
REINHARDT MAX	President, Rest of World	Jun 07	Sale	60.50	2,278	137,819	10,500	Jun 08 04:16 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 04	Sale	61.04	3,930	239,875	20,957	Jun 08 04:20 PM
WINSTON ROY	Chief Clinical Officer	Jun 04	Sale	61.04	2,276	138,920	24,035	Jun 08 04:20 PM
STACK DAVID M	CEO and Chairman	Jun 04	Sale	61.04	14,905	909,756	61,156	Jun 08 04:18 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 04	Sale	61.04	2,648	161,626	24,799	Jun 08 04:17 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 04	Sale	61.04	1,047	63,906	12,134	Jun 08 04:17 PM
REINHARDT MAX	President, Rest of World	Jun 04	Sale	61.04	1,222	74,587	12,778	Jun 08 04:16 PM
McLoughlin Dennis	Chief Customer Officer	Jun 04	Sale	61.04	1,895	115,665	27,541	Jun 08 04:15 PM
LARANJEIRA CHARLES ANTHONY	Chief Technical Officer	Jun 04	Sale	61.04	2,117	129,215	18,681	Jun 08 04:14 PM
HASTINGS PAUL J	Director	Jun 04	Sale	62.19	630	39,180	5,486	Jun 08 04:13 PM
Manning Donald C.	Chief Medical Officer	Jun 02	Sale	62.12	2,380	147,853	26,120	Jun 04 05:27 PM
STACK DAVID M	CEO and Chairman	May 12	Option Exercise	10.81	21,250	229,712	97,311	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 12	Sale	61.95	21,250	1,316,471	76,061	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 11	Option Exercise	10.81	21,250	229,712	97,311	May 13 06:01 PM
STACK DAVID M	CEO and Chairman	May 11	Sale	60.93	21,250	1,294,827	76,061	May 13 06:01 PM
Williams Kristen Marie	Chief Administrative Officer	Apr 13	Option Exercise	40.28	21,823	878,943	46,710	Apr 15 08:35 PM
Williams Kristen Marie	Chief Administrative Officer	Apr 13	Sale	66.95	21,823	1,461,068	24,887	Apr 15 08:35 PM
WINSTON ROY	Chief Clinical Officer	Mar 31	Option Exercise	34.38	13,750	472,656	48,535	Apr 02 06:33 PM
WINSTON ROY	Chief Clinical Officer	Mar 31	Sale	70.61	22,224	1,569,195	26,311	Apr 02 06:33 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 17	Option Exercise	10.81	2,000	21,620	15,181	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 17	Sale	70.01	2,000	140,020	13,181	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 15	Option Exercise	10.81	1,520	16,431	14,701	Mar 17 08:03 PM
Riker Lauren Bullaro	Vice President, Finance	Mar 15	Sale	73.28	1,520	111,386	13,181	Mar 17 08:03 PM
Froimson Mark	Director	Mar 15	Sale	72.26	734	53,039	5,242	Mar 17 08:01 PM
Wicki Andreas	Director	Mar 15	Sale	73.68	10,601	781,082	451,324	Mar 16 09:12 PM
Wicki Andreas	Director	Mar 12	Sale	73.10	58,754	4,294,917	461,925	Mar 16 09:12 PM
Wicki Andreas	Director	Mar 11	Sale	72.70	60,574	4,403,730	520,679	Mar 11 09:37 PM
Wicki Andreas	Director	Mar 10	Sale	71.78	76,480	5,489,734	581,253	Mar 11 09:37 PM
Wicki Andreas	Director	Mar 09	Sale	70.90	35,137	2,491,213	657,733	Mar 11 09:37 PM
HASTINGS PAUL J	Director	Mar 05	Option Exercise	13.98	3,000	41,940	9,116	Mar 09 04:12 PM
HASTINGS PAUL J	Director	Mar 05	Sale	65.88	3,000	197,640	6,116	Mar 09 04:12 PM
LONGENECKER JOHN P PHD	Director	Mar 01	Option Exercise	13.98	5,000	69,900	22,757	Mar 03 04:25 PM
LONGENECKER JOHN P PHD	Director	Mar 01	Sale	72.26	5,000	361,300	17,757	Mar 03 04:25 PM
STACK DAVID M	CEO and Chairman	Feb 03	Option Exercise	10.81	21,250	229,712	97,311	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 03	Sale	71.21	21,250	1,513,259	76,061	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 02	Option Exercise	10.81	21,250	229,712	97,311	Feb 04 07:58 PM
STACK DAVID M	CEO and Chairman	Feb 02	Sale	69.41	21,250	1,474,874	76,061	Feb 04 07:58 PM
REINHARDT MAX	President	Jan 06	Sale	60.81	110	6,689	14,000	Jan 08 04:39 PM
Brege Laura	Director	Nov 16	Option Exercise	13.98	12,000	167,760	19,921	Nov 17 05:39 PM
Brege Laura	Director	Nov 16	Sale	65.95	12,000	791,400	7,921	Nov 17 05:39 PM
REINHARDT MAX	President	Nov 13	Option Exercise	42.54	25,000	1,063,500	39,000	Nov 17 05:28 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 13	Option Exercise	10.81	3,000	32,430	16,181	Nov 17 05:37 PM
Riker Lauren Bullaro	Vice President, Finance	Nov 13	Sale	63.81	3,000	191,430	13,181	Nov 17 05:37 PM
WINSTON ROY	Chief Clinical Officer	Nov 13	Sale	62.00	5,000	310,000	34,785	Nov 17 05:30 PM
REINHARDT MAX	President	Nov 13	Sale	63.38	25,000	1,584,390	14,000	Nov 17 05:28 PM
STACK DAVID M	CEO and Chairman	Oct 16	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 16	Sale	55.56	30,000	1,666,800	173,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 15	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 15	Sale	55.00	30,000	1,650,000	173,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 14	Option Exercise	10.81	30,000	324,300	203,377	Oct 16 04:26 PM
STACK DAVID M	CEO and Chairman	Oct 14	Sale	55.53	30,000	1,665,900	173,377	Oct 16 04:26 PM
PACE GARY W	Director	Sep 25	Option Exercise	16.67	70,000	1,166,900	129,949	Sep 29 05:16 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 17	Option Exercise	39.19	27,871	1,092,268	52,758	Sep 17 07:13 PM
REINHARDT MAX	President	Sep 17	Option Exercise	42.54	25,000	1,063,500	39,000	Sep 21 06:23 PM
REINHARDT MAX	President	Sep 17	Sale	59.81	25,420	1,520,318	14,000	Sep 21 06:23 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 17	Sale	59.82	27,871	1,667,290	24,887	Sep 17 07:13 PM
Riker Lauren Bullaro	Vice President, Finance	Sep 16	Option Exercise	10.81	3,000	32,430	16,181	Sep 17 07:10 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 16	Option Exercise	39.19	27,853	1,091,560	52,740	Sep 17 07:13 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 16	Sale	60.14	27,853	1,675,150	24,887	Sep 17 07:13 PM
Riker Lauren Bullaro	Vice President, Finance	Sep 16	Sale	60.34	3,000	181,020	13,181	Sep 17 07:10 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 15	Option Exercise	39.19	27,853	1,091,560	52,740	Sep 17 07:13 PM
Williams Kristen Marie	Chief Administrative Officer	Sep 15	Sale	59.39	27,853	1,654,058	24,887	Sep 17 07:13 PM
Wicki Andreas	Director	Sep 09	Sale	62.02	2,216	137,436	692,970	Sep 11 08:03 PM
STACK DAVID M	CEO and Chairman	Aug 17	Sale	61.91	15,000	928,619	173,377	Aug 19 05:44 PM
Wicki Andreas	Director	Aug 13	Sale	61.47	34,904	2,145,549	695,186	Aug 13 08:58 PM
Wicki Andreas	Director	Aug 12	Sale	60.82	113,500	6,903,070	730,090	Aug 13 08:58 PM
Riker Lauren Bullaro	Vice President, Finance	Aug 11	Option Exercise	10.34	8,180	84,581	20,813	Aug 13 04:35 PM
Wicki Andreas	Director	Aug 11	Sale	61.32	106,772	6,546,747	843,590	Aug 13 08:58 PM
Riker Lauren Bullaro	Vice President, Finance	Aug 11	Sale	60.50	8,180	494,890	13,181	Aug 13 04:35 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Aug 03	Option Exercise	44.10	2,500	110,250	22,750	Aug 05 05:16 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Aug 03	Sale	52.68	2,500	131,700	20,796	Aug 05 05:16 PM
STACK DAVID M	CEO and Chairman	Jul 15	Sale	56.88	12,000	682,560	188,377	Jul 17 05:44 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Jun 29	Option Exercise	42.07	56,250	2,366,588	80,351	Jul 01 09:17 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 29	Option Exercise	10.34	6,000	62,040	18,633	Jul 01 09:20 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 29	Sale	49.47	6,000	296,800	12,633	Jul 01 09:20 PM
LARANJEIRA CHARLES ANTHONY	SVP, Technical Operations	Jun 29	Sale	50.27	60,101	3,021,314	20,250	Jul 01 09:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience